Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children [clinicaltrials:NCT00000893]
Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children [clinicaltrials:NCT00000893]
Bio2RDF identifier
NCT00000893
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00000893
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
Cohort I: The purpose o ...... use in combination with EFZ.
brief title [clinicaltrials_vocabulary:brief-title]
Safety, Tolerability, and Anti ...... navir in HIV-Positive Children
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2002-12-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
The demonstrated antivi ...... 04] [APA 5/8/00: 208] weeks.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-02T00:00:00Z
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Area Under Curve
Dose-Response Relationship, Drug
Drug Therapy, Combination
HIV Protease Inhibitors
Nelfinavir
Reverse Transcriptase Inhibitors
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2015-06-02T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00000893
official title [clinicaltrials_vocabulary:official-title]
A Phase I/II, Open-Label, AUC- ...... on With Nelfinavir in Children
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1997-10-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2015-06-01T00:00:00Z
identifier
clinicaltrials:NCT00000893
title
Safety, Tolerability, and Anti ...... navir in HIV-Positive Children
@en
type
label
Safety, Tolerability, and Anti ...... n [clinicaltrials:NCT00000893]
@en